Baxter International Inc. (NYSE:BAX – Get Rating) – Analysts at SVB Leerink dropped their Q1 2022 earnings estimates for Baxter International in a report released on Monday, April 18th. SVB Leerink analyst D. Antalffy now anticipates that the medical instruments supplier will earn $0.75 per share for the quarter, down from their prior forecast of $0.81. SVB Leerink also issued estimates for Baxter International’s Q4 2022 earnings at $1.42 EPS.
Baxter International (NYSE:BAX – Get Rating) last posted its quarterly earnings results on Thursday, February 17th. The medical instruments supplier reported $1.04 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.01. The company had revenue of $3.51 billion for the quarter, compared to the consensus estimate of $3.35 billion. Baxter International had a return on equity of 21.01% and a net margin of 10.04%. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.80 EPS.
Shares of Baxter International stock opened at $74.97 on Tuesday. The stock’s fifty day simple moving average is $80.82 and its 200 day simple moving average is $81.70. The company has a current ratio of 2.09, a quick ratio of 1.52 and a debt-to-equity ratio of 1.88. The company has a market capitalization of $37.72 billion, a PE ratio of 29.63, a PEG ratio of 1.71 and a beta of 0.60. Baxter International has a 12 month low of $73.12 and a 12 month high of $89.70.
The business also recently announced a quarterly dividend, which was paid on Friday, April 1st. Shareholders of record on Friday, February 25th were issued a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 1.49%. The ex-dividend date was Thursday, February 24th. Baxter International’s payout ratio is presently 44.27%.
In other news, CAO Brian Stevens sold 2,500 shares of the stock in a transaction on Monday, February 28th. The stock was sold at an average price of $85.50, for a total transaction of $213,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Albert P. L. Stroucken sold 4,020 shares of the company’s stock in a transaction that occurred on Tuesday, April 5th. The shares were sold at an average price of $76.02, for a total transaction of $305,600.40. Following the sale, the director now owns 27,629 shares in the company, valued at $2,100,356.58. The disclosure for this sale can be found here. Corporate insiders own 0.21% of the company’s stock.
A number of large investors have recently made changes to their positions in BAX. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its stake in Baxter International by 2,348.0% in the 3rd quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 1,224 shares of the medical instruments supplier’s stock worth $98,000 after buying an additional 1,174 shares in the last quarter. Waldron Private Wealth LLC grew its stake in Baxter International by 9.2% in the 3rd quarter. Waldron Private Wealth LLC now owns 4,900 shares of the medical instruments supplier’s stock worth $395,000 after acquiring an additional 414 shares in the last quarter. John G Ullman & Associates Inc. boosted its holdings in shares of Baxter International by 48.4% in the third quarter. John G Ullman & Associates Inc. now owns 21,677 shares of the medical instruments supplier’s stock valued at $1,743,000 after purchasing an additional 7,067 shares during the period. Dupont Capital Management Corp raised its position in shares of Baxter International by 21.0% in the 3rd quarter. Dupont Capital Management Corp now owns 19,768 shares of the medical instruments supplier’s stock worth $1,590,000 after acquiring an additional 3,427 shares in the last quarter. Finally, Red Cedar Investment Management LLC purchased a new stake in shares of Baxter International during the 3rd quarter worth $914,000. 84.11% of the stock is currently owned by institutional investors and hedge funds.
About Baxter International (Get Rating)
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.
- Get a free copy of the StockNews.com research report on Baxter International (BAX)
- 3 No-Brainer Stocks to Buy with $1000
- Rite Aid Stock is Getting Cheap Enough to Buy Here
- Analysts Reel In Netflix Targets Ahead Of Q1 Earnings
- MarketBeat Podcast: Making Money in the Red-Hot Housing Market
- Banking On Bank Of America
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.